Your web browser doesn’t have the Flash Player v.18 plugin installed, so this Website can’t be properly viewed.
For full experience, please download the latest Flash plugin at Adobe.com.
Download Adobe Flash Player now.

GARDASIL®

Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine


PROTECTION WITH GARDASIL®

GARDASIL® is a vaccine that helps protect against 4 types of human papillomavirus (HPV): 2 types that cause 70% of cervical cancers in women and 80-90% of HPV-related anal cancers in men and women, and 2 more types that cause 90% of genital warts in men and women.

GARDASIL® has also been shown to help protect against vulvar and vaginal cancers, as well as abnormal and precancerous cervical cells (as found in abnormal Pap tests) in women.

WHO SHOULD GET VACCINATED WITH GARDASIL®?

GARDASIL® is for girls and women ages 9 to 45, and boys and men ages 9 to 26. Vaccination is recommended for girls and boys as young as 9 because GARDASIL® works best when given before there is any contact with HPV types 6, 11, 16, and 18.

But, if you’re already sexually active, you can still benefit from GARDASIL®. If you are already infected with one type of HPV contained in the vaccine, GARDASIL® will help protect you against the other three types. That means GARDASIL® could still help protect you against HPV types you haven’t been exposed to.

As with all vaccines, GARDASIL® may not fully protect everyone who gets the vaccine. GARDASIL® will not protect against all types of HPV, and it will not protect against other diseases that are not caused by HPV. Your healthcare professional can help you understand more.

If you are considering GARDASIL® for your son or your daughter, learn more here.

3 DOSES FOR PROTECTION

GARDASIL® is given in 3 doses over 6 months.

Alternatively, individuals 9 through 13 years of age, may receive 2 doses of the vaccine.


IMPORTANT INFORMATION ABOUT GARDASIL®

In girls and women ages 9 to 45, GARDASIL® helps prevent infection caused by HPV types 6, 11, 16 and 18 and the following diseases associated with the HPV types included in the vaccine: cervical, vaginal, and vulvar cancers caused by HPV types 16 and 18; abnormal and precancerous vaginal and vulvar lesions, abnormal and precancerous cervical lesions as found in Pap tests, caused by types 6, 11, 16 and 18; and genital warts caused by types 6 and 11.

In girls and women ages 9 to 26, GARDASIL® also helps protect against anal cancer caused by HPV types 16 and 18, and abnormal and precancerous anal lesions caused by types 6, 11, 16 and 18.

In boys and men ages 9 to 26, GARDASIL® helps protect against infection caused by HPV types 6, 11, 16 and 18 and the following diseases associated with the HPV types included in the vaccine: anal cancer caused by HPV types 16 and 18, genital warts caused by types 6 and 11, and abnormal and precancerous anal lesions caused by types 6, 11, 16 and 18.

GARDASIL® helps prevent these diseases, but it does not treat them. And just like all vaccines, GARDASIL® may not fully protect everyone who gets it. GARDASIL® does not protect against all types of HPV. Duration of protection continues to be studied. GARDASIL® does not protect against other sexually transmitted infections.

Even if vaccinated with GARDASIL®, it is still important for women to continue having regular Pap tests. Recipients of GARDASIL® should not discontinue anal cancer screening if it has been recommended by a healthcare provider. Vaccination with GARDASIL® is not recommended during pregnancy.

Like all vaccines, GARDASIL® may cause some side effects. GARDASIL® has been shown to be generally well tolerated in adults and children as young as age 9. The most commonly reported side effects included pain, swelling, itching, bruising and redness where the shot was given, fever, nausea, dizziness, headache, vomiting and pain in extremity.

Fainting has been reported. Fainting can occur after vaccination, most commonly among adolescents and young adults. Although fainting episodes are uncommon, vaccinees should be observed for 15 minutes after they receive GARDASIL®.

Allergic reactions that may include difficulty breathing, wheezing (bronchospasm), hives, and rash have been reported.

These were not all the side effects reported. If you notice any unusual or severe symptoms after receiving GARDASIL®, contact your healthcare professional as soon as possible.

Information about GARDASIL® is provided in the Consumer Information. To retrieve this information you will be re-directed to a page within our main Merck Website, which contains the Consumer Information.

Click here to go to the Gardasil® Consumer Information.

To view PDF documents, you must have Adobe Acrobat Reader®

To view PDF documents, you must have Adobe Acrobat Reader® By clicking on this link, you will be leaving this site This link will take you to a site outside of Merck Canada Inc.

Merck does not review or control the content of any non-Merck site. Merck does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Merck site.
Proceed
installed on your computer.






This site is intended only for residents of Canada. This Website is for information purposes only.
® Merck Sharp & Dohme Corp. Used under license.

© 2016 Merck Canada Inc. All rights reserved.
VACC-1158121-0000 FE 2017